Sitemap
-
Science
-
Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
-
Cutting Edge Science
-
2022
- Rapidly identifying thrombotic thrombocytopenic purpura (TTP) can save lives¹
- Rapidly identifying thrombotic thrombocytopenic purpura (TTP) can save lives¹
- Rapidly identifying thrombotic thrombocytopenic purpura (TTP) can save lives¹
- Tools to support a clinical aTTP diagnosis
- Rapidly identifying thrombotic thrombocytopenic purpura (TTP) can save lives¹
- ISTH Guidelines
- 2023
-
2024
-
2022
-
Cutting Edge Science
- Allergic Rhinitis
- Anti-Infectives
-
Asthma
-
Cutting Edge Science
- 2021
-
Innovation
- What is your experience with Dupixent in your practice?
- How does Dupixent help reduce asthma exacerbations across multiple phenotype.
- Why is it important to measure FEV1 in patients with asthma?
- Prevalence of Asthma
- Asthma Assessment Tools (EPOS)
- Managing Severe Asthma and CRSwNP through the lens of type 2 inflammation
- What feedback have you received from patients being treated with Dupixent?
- What beneficial impact does Dupixent have on OCS-Dependent patients?
- How does Dupixent target the underlaying type2 inflammation in asthma?
- What gives you confidence that Dupixent improves patients’ quality of life?
- Dupixent reduce Asthma Exacerbation across different type of patients
- Why is it important to look for Type 2 inflammation in patients with Asthma?
- How do you balance the cost of Biologics with the value they can bring to patients?
- How Type 2 inflammation affect patients with Asthma?
- What challenges do you face when treating patients with Type 2 inflammation?
- When do you discuss Biologic treatment with your Asthma patients?
- How do you choose the right Biologic for a particular Asthma patients?
- Asthma Control Tests (ACT) overview
- 2023
- 2024
-
Cutting Edge Science
- Atopic Dermatitis
-
Cardiovascular
-
Atherothrombosis
-
Cutting Edge Science
- Innovation
-
2022
- Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice
- In hospital outcomes in young patients with AMI: Results from Gulf Coast
- Adherence and persistence analysis in patients treated with DAPT
- Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)
- Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?
-
2023
- De-escalation to Clopidogrel in AMI
- Clopidogrel vs aspirin post PCI following DAPT
- Ticagrelor vs Clopidogrel in high bleeding risk patients with ACS
- P2Y12 inhibitors after Coronary stenting
- Smart-choice trial_P2Y12 inhibitor monotherapy in complex PCI
- The SWITCH study: antiplatelet-switching strategy after coronary interventions
- ESC 2021 - Antiplatelet therapy in high bleeding risk patients with or without OAC therapy
- ESC 2021 - Dual Antiplatelet Therapy After Coronary Stenting in High Bleeding Risk Patients
- DAPT for secondary prevention of AIS
- Clopidogrel Based Strategies in ACS
- Net clinical benefit of Clopidogrel vs Ticagrelor
- New Users of Ticagrelor / Clopidogrel Observational Study in Sweden
- Clopidogrel vs Ticagrelor in ACS
- Ticagrelor vs Clopidogrel in high bleeding risk patients with ACS
- De-escalation of DAPT for ACS
- Unguided de-escalation from Ticagrelor to Clopidogrel
- Potent P2Y12 Inhibitors vs Clopidogrel in elderly ACS patients
- DAPT de-escalation vs standard DAPT
- Clopidogrel monotherapy after very short DAPT
- P2Y12 inhibitor adherence trajectories in ACS
- Clinical outcome of switching from Clopidogrel to Ticagrelor
-
Cutting Edge Science
-
Dyslipidemia
-
Cutting Edge Science
-
2021
- Heart UK Reviews Safety of Lipid Lowering Medications in Patients with COVID-19
- The ACTE Study
- The ROSETTE Study
- The Explorer Study
- Regulate LDL-C level for those undergoing coronary revascularization (Diabetic Patients)
- Real-life safety and efficacy of Alirocumab - Odyssey apprise study
- Optimal use of LLT after ACS
- Italian real-world analysis for PCSK9 inhibitors new users
- NEJM Odyssey outcomes
- Odyssey outcomes
- Odyssey outcomes - DM sub-analysis
- Odyssey outcomes - elderly patients results
- Odyssey outcomes - CABG results
- Odyssey outcomes - PVD results
- Odyssey outcomes - total events results
- Odyssey outcomes - mortality
- ESC/EAS 2019 international guidelines
- Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress
- Odyssey Outcomes - PVD Sub-analysis
- Odyssey Outcomes - Total Events Analysis
- Odyssey outcomes - CVOT mortality sub-analysis
- Effect of Alirocumab on MACE in patients with CKD
-
Innovation
- Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)
- Statin/ezetimibe SPC for better adherence to LLT
- Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients
- Lp(a) as ASCVD risk factor
- Atherosclerosis: Identifying risks and improving outcomes
- Managing the Recurrent ASCVD Risks of Your ACS Patient: A call to Action – GULF Perspective: Part 3
- Managing Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 2
- Managing the Recurrent ASCVD Risks of Your ACS Patient: Gulf Perspective (Part 1)
- Metabolic Risk Factors and Effect of Alirocumab on CV Events
- Act Now for Your ACS Patients: Optimize Your ACS Pathway
- Act Now for Your ACS Patients: Summary
- Act Now for Your ACS Patients: Patient Identification
- Overview of adherence data with LLT highlighting the most recent data with PCSK9i
- Treating to target in clinical practice: Why is it important to achieve recommended LDL-C levels?
- Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early
- Improving Lipid Management for Patients Post-ACS
- Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines
- The role of the patient in Achieving LDL-C Target
- Identifying and treating patients with high Lipidaemia risk post-ACS
- EAS guidance regarding combining Lipid-modifying therapy
- Lipid management in patients with ACS/ASCVD
- 2022
-
2022
- Achievement of lipid modification goals with Statins & Ezetimibe
- Single-Pill Combinations in Dyslipidemia
- Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia
- Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines
- Evaluation of lipid management following ACS
- Use of Lipid-Lowering Therapies Over 2 Years
- The European experience: Swedeheart and AIFA registries
- Perceptions and Barriers on the use of PCSK9 inhibitors
- Clinical practice experience in patients with familial hypercholesterolemia (FH) from the Safeheart registry
- PCSK9 inhibitors and ACS
- Prognostic impact of achieving LDL cholesterol guidelines
- Statin/Ezetimibe Combination VS Statin Monotherapy
- Should we encourage earlier and broader use of combination therapies in dyslipidemia?
- Possible Challenges Post One Year of ESC/EAS Guidelines
- PCSK9i after hospital discharge for acute MI
- PCSK9 Inhibitors in Real World Practice
- PCSK9i and Prevention of CVD
- Achievement of ESC/EAS LDL-C Treatment Goals After an ACS with Statin and Alirocumab
- LDL-C The Only Causal Risk Factor for ASCVD
- APSC Consensus Recommendations on Dyslipidemia
- CV Risk management in T1DM using guidelines
- Atherosclerotic Cardiovascular Disease Risk Assessment
- ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci
- Event rates and Risk Factors for Recurrent CV Events
- Role of Genetic Testing in Management of Dyslipidemia
- PCSK9 Inhibitors in Cardiovascular Disease
- LLTs and Antithrombotic Therapy in PAD
- What do us physicians and patients think about LLTs and goals of treatment?
- Importance of lipid registries in cardiovascular prevention
- LDL-C in the management of high cardiovascular risk, changing the paradigm for prevention
- LDL-C Targets in Patients with Heterozygous Familial Hypercholesterolemia
- Public health recommendations for Lp(a) measurement
- Relationship Between LDL-C LLTs and Risk of Stroke
- ESC Lp(a) in Clinical practice EAS Consensus statement
- Why compromise for less: Should PCSK9 inhibitors be initial therapy?
- LLTs Exposure Time and Major Vascular Risk Reduction
-
2023
- Cardiovascular Disease in Saudi Arabia: Facts and the Way Forward
- Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study
- Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia
- Hypercholesterolemia Treatment Patterns and Lipid Target in ACS Patients: HYDRA-ACS Registry
- Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice
- Meta Analysis of apoB Lowering and CV Risk Reduction Among Different LLTs
- Lp(a) Levels in Global ASCVD Patients
- Efficacy of PCSK9i on Lipid Residual Risk Lipid Real Registry
- 2022 ACC Expert Consensus on ASCVD Management
- LLT and LDLC Over 2 years in CKD and ASCVD From the Gould Registry
- 2024
-
2021
-
Cutting Edge Science
- Hypertension
-
Thrombosis
-
Cutting Edge Science
-
2022
- Changing trends in VTE: Pulmonary Embolism cases on Rise within the Last Decade
- Global use of RAM and Thromboprophylaxis in hospitalized patients
- Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients
- Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients
- Benefit of Prophylaxis for High-Risk Surgical Patients
- Independent Risk Factors for Venous Thromboembolism
- Specific Patient Characteristics Linked to Below Average Quality of Life in Patients with Recent Venous Thromboembolism (VTE)
- Prolonged Thromboprophylaxis with LMWH after Abdominal or Pelvic Surgery
- Risk for Post-operative Venous Thromboembolism in Patients Receiving Enoxaparin Prophylaxis
- Trends in Pulmonary Embolism-related mortality in Europe
- 2019 ESC Guidelines for Acute Pulmonary Embolism
- Risk for Pulmonary Embolism Continues Beyond 6 Weeks of Surgery
- VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients
- Utility of Pregnancy - Adapted Years Algorithm in Diagnosis of Pulmonary Embolism
- Maternity Clot Risk Model to Predict Women at Risk of VTE
- Major GI Bleeding in VTE RIETE Analysis
- Caprini Score Responses to Prevent VTE in Patients Undergoing Varicose Vein Surgery
- Innovation
-
2023
- DVT in Post-partum Case of Caesarean Section
- VTE Incidence after Cesarean Delivery in Selected Guidelines
- Low risk of VTE Following Early Pregnancy Loss in Pregnancies Conceived by IVF
- Maternal and Perinatal Outcomes of VTE
- Recurrence of VTE in Patients with Recent Gestational DVT or PE
- Post Thrombotic Syndrome in Women
-
2022
-
Cutting Edge Science
- Cutting Edge Science
-
Atherothrombosis
- Chronic Obstructive Pulmonary Disease
-
Diabetes
-
Cutting Edge Science
-
2021
- Effectiveness of continuous glucose monitoring in adults with Type 2 diabetes treated with basal insulin
- Unmet needs in adults with T2D receiving premixed insulin
- Exploring the risk for severe hypoglycemia in the pool of studied patients with T1D
- The Bright Study
- New technologies in Type 2 Diabetes management and future opportunities to improve clinical outcomes
- Insulin Treatment Intensification with GLP - 1RA vs Basal - Plus/Basal - Bolus Regimens
- Hospitalization Rates for Acute Diabetes Complications Before and After Flash Glucose Monitoring Initiation Among People with Type 1 or Type 2 Diabetes in France: The Relief Study
- A Cross-Sectional Analysis of Glycemic Control in Elderly People with Type 2 Diabetes Attending Primary Health Care Unit
- Basal Insulin and Beyond: Advanced Therapies for Type 2 Diabetes
- Prevalence of Diabetes in Children and Adolescents
- Reducing risk of severe hypoglycemia - iNPHORM Study
- The Lixilan-L Study
-
Innovation
- Insulin advancement in Type 2 diabetes: Unmet needs with commonly-used options
- Challenges associated with commonly-used insulin advancement options
- EVOLUTION: RWE from Saudi Arabia
- Treatment simplification of complex insulin regimens in T2D
- Advancing Therapy with iGlarLixi: Differentiation from complex insulin regimens
- Advancing Therapy with iGlarLixi: Differentiation from other complex regimens
- Glargine 300 use in people with type 2 diabetes who fast during Ramadan
- National Diabetes Training Program For Primary health care physicians in KSA
- The burden associated with insulin self-management
- Titration Inertia; A Predominant Issue for People with Diabetes
- ATTD 2021: Technology Supporting Initiation, Titration, and Intensification
- The InRange Study
- Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options
- Time-In-Range (TIR): How to interpret it and how it is associated with outcomes
- SoliMix Study Results Summary
- T1D Treatment Practice and the SAGE Study
- T1DM Mini-Series: The main challenge for the kids and adolescents with T1
- T1DM Mini-Series: Severe hypoglycaemia compromises the achievement of glycaemic control
- Do historical HbA1c values explain glycemic legacy effect in type 2 diabetes?
- T1DM Mini-Series: Clinical implications of having hyperglycaemia with ketosis
- Diabetes Your Type: Testimonial by Dr. Bassam
- T1DM Mini-Series: Edition Junior trial results
- T1DM Mini-Series: Relevance of Edition JUNIOR trial results for the HCP and Patient life
- T1DM Mini-Series: How does Hypoglycaemia impact the life of people with T1 Diabetes?
- T1DM Mini-Series: How to Avoid Hypoglycaemia in People with T1 Diabetes?
- The SoliRam observational study
- Expert consensus statement on management of older adults with type 2 diabetes (T2D)
- Is Premixed Insulin an Effective Treatment for Type 2 Diabetes Uncontrolled by OADs?
- Summary of SAGE study on Adults with T1DM
- ATTD 2021: Patients’ profiles for digital tools
- The value of Time-in-range
- Impact of Time-In-Range on Diabetes Management
- What Is Time-in-Range?
- Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control
- Real-world evidence of treatment intensification in people with T2D inadequately controlled on GLP-1 RAs
- ADA 2021: Solimix Trial Summary
- Diabetes your type: Testimonial by Dr. Nadia
- Diabetes your type: Testimonial by Dr. Hussein
- 2022
-
2022
- Patient awareness and attainment of goals in Type 2 Diabetes Mellitus: A real-world survey
- Diabetes management during Ramadan
- iGlarLixi Enables Safe Ramadan Fasting for Most T2D Patients
- Post-exercise hypoglycemia in relation to medication regimen among adults with type 2 diabetes
- Recommendations on treatment simplification of complex insulin regimens to improve clinical outcomes in patients with T2DM
- Closed-loop insulin delivery during exercise in people with T1DM
- A narrative review for clinicians on insulin management for Type 2 Diabetes during Ramadan
- Single injectable treatment may not be enough to get T2DM patient to Glycemic goal
- Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement
- Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.
- 2023
-
2024
- Groundbreaking SoliD Study: Comparative Efficacy of iGlarLixi and IDegAsp
- SoliD: Redefine Treatment Paradigm Post-OAD
- Unveiling Significance of Time in Range: Value as key Glycemic Biomarker
- Need to redefine the treatment paradigm Post OAD
- SoliCGM Synergy: Soliqua’s Synchronized Impact on T2DM CGM Dynamics Therapy
- The Evolving Role of Treatment and Technology in Diabetes Care
- Time-in-Range: A Key Determinant of Quality of Life
- The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.
- An Evidence about The Role of Basal Insulin Glargine 300 U/mL Post-GLP-1 Therapy
- Connectivity Canvas: Pioneering Diabetes Management with Connected Insulin Caps
- Inside Diabetes: ATTD Edition | Type 2 Diabetes
- Inside Diabetes: ATTD Edition | Type 1 Diabetes
-
2021
-
Cutting Edge Science
- Eosinophilic Esophagitis
- Microbiota & Probiotics
-
Multiple Myeloma
-
Multiple Sclerosis
-
Cutting Edge Science
- Innovation
-
2022
- The reason for MS – beyond focal inflammation
- The importance of deep grey matter in MS
- Measuring brain atrophy. What can be done and where are we heading?
- Falling chronically ill – How do I cope and move forward?
- Cognitive decline – The invisible burden of MS?
- Cognitive training – A curse or a blessing?
- How old is your brain?
- Exercise as ”medicine” in the treatment of MS
- A promising biomarker in MS: Neurofilament light chain
- Why has our brain suddenly become of interest?
- Thalamic atrophy as a new biomarker of MS? The predictive value and how to use in clinical practice
- MS Updates
-
2023
-
Cutting Edge Science
- Neurological Disorders
-
Prurigo Nodularis
-
Cutting Edge Science
-
2022
- There is significant unmet need in the management of PN¹
- Mechanism of Prurigo Nodularis Disease
- Prurigo Nodularis is a distinct, Chronic, Neural and Immune- Mediated skin disease characterized by intense itch and Nodular Lesions¹
- Type 2 Inflammation may play a role in Prurigo Nodularis Pathophysiology1
- 2023
- 2024
-
2022
-
Cutting Edge Science
-
Rare Diseases
-
Cutting Edge Science
- 2022
-
2023
- Gaucher
- Differential Diagnosis Of Late Onset Pompe Disease (LOPD) and Myotonic Dystrophy Type 1 Through Abdominal Ultrasonography
- Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease for orthopedists
- Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease (LOPD)
- Experts recommendations on Late Onset Pompe Disease (LOPD) differential diagnosis from GCC
- Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
- Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
- Prevalence Of LOPD In Patients With Undifferentiated Proximal Myopathy And Undiagnosed Muscle Biopsy
- An overview of Lysosomal Storage Disorders & Sanofi`s Commitment to the Development and Provision of Treatments
- MPSI
- Fabry
- Pompe
-
2024
- Uncover ASMD and GAUCHER
- Legacy Video for Rare Disease Academy
- ASMD
- What Are the Signs and Symptoms of ASMD?
- Management of ASMD - Expert opinion: Professor Moeen Al Sayed
- Navigating the Pompe Disease Journey
- Impact of symptoms and risk of ASMD on patients and caregivers
- Consensus Guidelines for the Clinical Management of ASMD
- Differential diagnostics for ASMD in patients suspected to have GD
- DIAGNOSING FABRY DISEASE IN CLINICAL PRACTICE
- ROLE OF ECG IN DIFFERENTIAL DIAGNOSIS OF ANDERSON–FABRY DISEASE WITH HCM
- BIOCHEMICAL DIAGNOSTIC STRATEGY IN FEMALES SUSPECTED OF FABRY DISEASE
- Pompe Care Podcast Series
- Management of ASMD - Expert opinion: Professor Tawfeq Ben Omran
- Management of ASMD - Expert opinion: Professor Fatma Al- Jasmi
-
Cutting Edge Science
-
Transplant
-
Cutting Edge Science
-
2024
- Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation
- Advances in the biology of chronic GVHD
- Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study
- European Respiratory Society (ERS)/ European Society for Blood and Marrow Transplantation (EBMT) clinical practice guidelines on treatment of pulmonary cGvHD in adults
- Psychological & Economical impact
- Optimizing Treatment
- Other Treatment Options
- Treatment under Clinical Development
- Molecular Pathway
- Inflammation and Fibrosis Role
- Impact on Patients
- Understandig cGVHD
- Optimizing Treatment
- Impact on Patients
- Understandig cGVHD
-
2024
-
Cutting Edge Science
-
Vaccines
- Influenza
- Meningitis
- Pertussis Polio
-
RSV
-
Cutting Edge Science
- 2023
-
2024
- Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection
- SIBRO Recommendation
- Nirsevimab International Recommendation
- 2024 RSV International Congress ECMMID
- Beyfortus in Action ECMMID
- Implementing Beyfortus successfully
- Beyfortus®, an innovative immunization
- Implementing Beyfortus successfully (ES)
- Implementing Beyfortus successfully (FR)
- Beyfortus in Action
- Implementing Beyfortus successfully (US)
- 2024 RSV International Congress - ESPID
- Nirsevimab : Clinical Experience
- Real World Evidence Impact of universal immunization with Nirsevimab
-
Cutting Edge Science
- Nasal Polyps
-
Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
-
Patient Support
- Atopic Dermatitis
-
Diabetes
- 2021
- Innovation
-
Tools and Resources
- My Dose Coach - Register your Clinic
- My Dose Coach - Real World Evidence
- My Dose Coach - Patient Guide
- My Dose Coach - Self Titration
- My Dose Coach - Getting Started
- My Dose Coach - About MDC
- Pre-Ramadan assessment and Risk calculation for people with diabetes who want to fast during Ramadan
- Clinical and economic value of Soliqua - Pharmacist perspective
- My Dose Coach
- My Dose Coach Inquiry
- MyDose Coach
-
Products
- Aldurazyme®
- Apidra®
- Aprovasc®
- Aubagio®
- Beyfortus®
- Cablivi®
- Cerezyme®
- Clexane®
- Dupixent®
- Fabrazyme®
- Myozyme®
- Nexviazyme
- Plavix®
- Renvela®
- Rezurock®
- Sarclisa®
- Solian®
- Soliqua®
- SoloSmart®
- Toujeo®
- Xatral®
- Xenpozyme®
- Zympass®
-
Events
- Dia-Tour: Navigating New Destinations in Diabetes Management
- Fabry Monitoring Matters Webinar Series
- Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management
- Diatour Inquiry Form
- Pharmacy Academy Webinar
- 5th Rare Disease Academy
- Soliqua and Unmet Needs Webinar Summary
- VTE Safety Zone: Prof. Juan Arcelus - Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery
- Innovation of Iglarlexi in Intensification
- Innovation of Iglarlexi in Intensification
- Ultimate Need for Intensification
- The Role of Basal Insulin in Type 2 Diabetes Webinar
- Leveraging Time-In-Range to Improve Patient Experience
- Amaryl Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management
- GAED 2023
- Cardiometabolic Approach in Diabetes Management
- Navigate new destinations in diabetes management
- Type 2 Diabetes Cost Effective Management
- Do not Keep it masked! Prof. Fatih Ezgü
- Introduction to Gaucher Disease by Prof. Moeenaldeen D. Alsayed
- ASMD: Overview And Clinical Cases - by Prof. Roberto Giugliani
- Dr. Rana Felemban lecture on MPS disease
- Prof. Christina Lampe lecture on MPSI disease
- Intro to Multiple Sclerosis by Dr Naji Riachi
- Diabetes Guidelines in Ramadan
- Multiple Sclerosis Diagnosis and Misdiagnosis by Prof. Bassem Yamout
- Nutrition and Insulin management in Ramadan
- Aubagio® - Impact on Brain Health and Real World Efficacy by Dr. Ahmed Shatila
- World Hypertension Day Ep. 2
- Personalized Therapy in RMS - Which DMT to Use and When? Professor Peter Rieckmann
- World Hypertension Day Ep. 1
- KSUMC Aubagio experience
- Pathology of chronic Smouldering MS SKMC Experiences - Dr.Mustafa Shakra
- A Patient's Journey on Teriflunomide: insights into Long-Term Treatment
- Challenges of VTE Prophylaxis in Surgery
- MSXChange l MS and Women
- Venous Thromboembolism in Acutely Medically Ill Patients
- The Underlying Biology of Neuroinflammation
- Venous Thromboembolism Burden
- Type 2 Inflammation and Prurigo Nodularis
- What is Epilepsy
- World Epilepsy Day Podcast Ep. 1
- World Epilepsy Day Podcast Ep. 2
- World Epilepsy Day Podcast Ep. 3
- Dyslipidemia Webisodes: Mortality data with Prof. Tunon
- Dyslipidemia Expert Exchange: Best practice approaches in dyslipidemia management
- Safe & Smart - Dr. Nabil
- Safe & Smart - Dr. Salah
- World Diabetes Day
- Safe & Smart - Dr. Khudhair
- Safe & Smart - Dr. Kalra
- Sir Robin Murray updates us on Schizophrenia and it’s treatments
- VTE Safety Zone: Assessing the VTE Risk in Hospital and Beyond
- CardioRisk WebApp
- Hypertension and CVD
- VTE Safety Zone: VTE in general surgery from risk assessment to appropriate thromboprophylaxis
- VTE Safety Zone: Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery
- Roadmap to antimicrobial prescribing
- VTE Safety Zone: The Role of Thromboprophylaxis for the Prevention of VTE
- Action and Resistance Mechanisms of Antibiotics
- Dyslipidemia Webinars: Optimizing Dyslipidemia management
-
Cardiovascular
-
2021
- VTE Safety Zone: Prof. Juan Arcelus - Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery
- Dyslipidemia Expert Exchange: Best practice approaches in dyslipidemia management
- VTE Safety Zone: Assessing the VTE Risk in Hospital and Beyond
- VTE Safety Zone: VTE in general surgery from risk assessment to appropriate thromboprophylaxis
- VTE Safety Zone: Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery
- VTE Safety Zone: The Role of Thromboprophylaxis for the Prevention of VTE
- Dyslipidemia Webinars: Optimizing Dyslipidemia management
- 2022
- 2023
-
2021
-
Diabetes
- 2021
-
2022
- Diatour Inquiry Form
- Innovation of Iglarlexi in Intensification
- Innovation of Iglarlexi in Intensification
- Ultimate Need for Intensification
- The Role of Basal Insulin in Type 2 Diabetes Webinar
- Leveraging Time-In-Range to Improve Patient Experience
- Navigate new destinations in diabetes management
- Type 2 Diabetes Cost Effective Management
- Diabetes Guidelines in Ramadan
- Nutrition and Insulin management in Ramadan
-
2023
- Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management
- Amaryl Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management
- GAED 2023
- Cardiometabolic Approach in Diabetes Management
- Safe & Smart - Dr. Nabil
- Safe & Smart - Dr. Salah
- World Diabetes Day
- Safe & Smart - Dr. Khudhair
- Safe & Smart - Dr. Kalra
- 2024
- Rare Disease
- Vaccines
- Multiple Sclerosis
- Prurigo Nodularis
- Neurological Disorders
- Anti Infectives
- Allergic Rhinitis
- Login
- Cookie Policy
- Legal Notice
- Privacy Policy
- Search
- Registration